Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD

doi:10.1016/j.metabol.2021.154958

科研成果详情

题名	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD
作者	Tang, Liang-Jie 1; Ma, Hong-Lei 1; Eslam, Mohammed 2; Wong, Grace Lai-Hung 3,4; Zhu, Pei-Wu5; Chen, Sui-Dan6; Leeming, Diana Julie 7; Karsdal, Morten 7; Li, Gang1; Huang, Ou-Yang1; Leung, Howard Ho-Wai 8; Zhou, Yu-Jie 9; Feng, Qian 10; Jiang, Pei 11; Gao, Li-Mei 11; Byrne, Christopher D.12; Targher, Giovanni 13; George, Jacob 2; Wong, Vincent Wai-Sun 3,4; Zheng, Ming-Hua1,14,15
发表日期	2022-03
发表期刊	METABOLISM-CLINICAL AND EXPERIMENTAL 影响因子和分区
语种	英语
原始文献类型	Article
关键词	Metabolic dysfunction-associated fatty liver disease N-terminal propeptide of type 3 collagen ADAPT Fibrosis staging
其他关键词	FATTY LIVER-DISEASE ; HEPATOCELLULAR-CARCINOMA ; CIRRHOSIS ; VARIABILITY ; PREDICT ; SYSTEM ; INDEX ; NAFLD
摘要	Background: With metabolic dysfunction-associated fatty liver disease (MAFLD) incidence and prevalence increasing, it is necessary to identify patients with advanced fibrosis (F3-F4 stages). We evaluated the performance of new biomarkers and algorithms for diagnosing advanced fibrosis in an Asian population. Methods: Data from two Asian cohorts (including 851 biopsy-proven MAFLD [578 from Wenzhou, 273 from Hong Kong]) were studied. The association between N-terminal propeptide of type 3 collagen (PRO-C3) and the histologic stage of liver fibrosis was analyzed by multivariable linear regression. The area under the receiver operating characteristic curve (AUROC) was used to test the diagnostic performance of serum PRO-C3 and the ADAPT score for advanced fibrosis and compared them to other established non-invasive tests. Results: Serum PRO-C3 levels increased progressively across liver fibrosis stages and correlated with advanced fibrosis (P < 0.001). The ADAPT score had an AUROC of 0.865 (95% confidence interval 0.829-0.901) for advanced fibrosis; the accuracy, sensitivity and negative predictive values were 81.4%, 82.2% and 96.1%, respectively. This result was better compared to that of PRO-C3 alone or other non-invasive fibrosis biomarkers (aspartate aminotransferase-to-platelet ratio index, Fibrosis-4, BARD, and NAFLD fibrosis score). In subgroup analyses (including sex, age, diabetes, NAFLD activity score, body mass index or serum alanine aminotransferase levels), the ADAPT score had good diagnostic performance. Conclusion: PRO-C3 and the ADAPT score reliably exclude advanced fibrosis in MAFLD patients and reduce the need for liver biopsy. (c) 2021 Elsevier Inc. All rights reserved.
资助项目	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82070588] ; High Level Creative Talents from Department of Health of Zhejiang Province [S2032102600032] ; Project of New Century 551 Talent Nurturing in Wenzhou ; School of Medicine, University of Verona, Verona, Italy ; Southampton NIHR Biomedical Research Centre [IS-BRC-20004] ; Chinese University of Hong KongChinese University of Hong Kong [2020.045] ; Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney ; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia [APP1053206, APP1196492, APP2001692, APP1107178, APP1108422]
出版者	W B SAUNDERS CO-ELSEVIER INC
出版地	PHILADELPHIA
ISSN	0026-0495
EISSN	1532-8600
卷号	128 页码:154958
DOI	10.1016/j.metabol.2021.154958
页数	7
WOS类目	Endocrinology & Metabolism
WOS研究方向	Endocrinology & Metabolism
WOS记录号	WOS:000754032000004
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	34958817
SCOPUSEID	2-s2.0-85122093125
通讯作者地址	[Wong, Vincent Wai-Sun]Department of Medicine and Therapeutics,9/F Prince of Wales Hospital, 30-32 Ngan Shing Street,Shatin,Hong Kong ; [Zheng, Ming-Hua]MAFLD Research Center,Department of Hepatology,the First Affiliated Hospital of Wenzhou Medical University,No. 2 Fuxue Lane,Wenzhou,325000,China
Scopus学科分类	Endocrinology, Diabetes and Metabolism;Endocrinology
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/20577
专题	附属第一医院附属第一医院_感染内科
通讯作者	Wong, Vincent Wai-Sun; Zheng, Ming-Hua
作者单位	1.MAFLD Research Center,Department of Hepatology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 2.Storr Liver Centre,Westmead Institute for Medical Research,Westmead Hospital,Westmead,and University of Sydney,Sydney,Australia; 3.Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong; 4.State Key Laboratory of Digestive Disease,The Chinese University of Hong Kong,Hong Kong; 5.Department of Laboratory Medicine,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 6.Department of Pathology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 7.Nordic Bioscience Biomarkers and Research A/S,Herlev,Denmark; 8.Department of Anatomical and Cellular Pathology,The Chinese University of Hong Kong,Hong Kong; 9.Division of Gastroenterology and Hepatology,Key Laboratory of Gastroenterology and Hepatology,Ministry of Health,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai Institute of Digestive Disease,Shanghai,China; 10.Department of Gastroenterology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 11.Fosun Diagnostics (Shanghai) Co.,Ltd,Shanghai,China; 12.Southampton National Institute for Health Research Biomedical Research Centre,University Hospital Southampton,Southampton General Hospital,Southampton,United Kingdom; 13.Section of Endocrinology,Diabetes and Metabolism,Department of Medicine,University and Azienda Ospedaliera Universitaria Integrata of Verona,Verona,Italy; 14.Institute of Hepatology,Wenzhou Medical University,Wenzhou,China; 15.Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province,Wenzhou,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Tang, Liang-Jie,Ma, Hong-Lei,Eslam, Mohammed,et al. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD[J]. METABOLISM-CLINICAL AND EXPERIMENTAL,2022,128:154958.
APA	Tang, Liang-Jie., Ma, Hong-Lei., Eslam, Mohammed., Wong, Grace Lai-Hung., Zhu, Pei-Wu., ... & Zheng, Ming-Hua. (2022). Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. METABOLISM-CLINICAL AND EXPERIMENTAL, 128, 154958.
MLA	Tang, Liang-Jie,et al."Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD".METABOLISM-CLINICAL AND EXPERIMENTAL 128(2022):154958.